News & Media
TLX101 for Brain Cancer IPAX-1 Study Update
Melbourne (Australia) – 23 December 2019. Telix Pharmaceuticals has released an update on the progress of its TLX101 product being developed for the treatment of glioblastoma multiforme (GBM)
Melbourne (Australia) – 23 December 2019
Telix Pharmaceuticals has released an update on the progress of its TLX101 product being developed for the treatment of glioblastoma multiforme (GBM, brain cancer). The IPAX-1 clinical trial, which is testing TLX101 combined with external beam radiation therapy in patients with recurrent GBM, is recruiting to plan. Early study outcomes appear encouraging.
To read the full media release click here.
More Articles
News
Positive FDA Feedback on NDA Submission Process for TLX591-CDx (kit for the preparation of 68Ga-PSMA-11)
Melbourne (Australia) – 25 Feb 2020. Telix Pharmaceuticals announces that it has received positive feedback from the FDA regarding its...
News
Telix Pharmaceuticals Releases Annual Report Year Ending 2019
Melbourne (Australia) - 24 Feb 2020. Telix Pharmaceuticals Limited is pleased to provide its Annual Report for the year ending...
News
European Leadership Changes and Appointment of VP Sales and Marketing, EMEA
Melbourne (Australia) – 21st February 2020. Telix Pharmaceuticals Limited announces that Ms Odile Jaume will be stepping down from her...
News
Telix Granted FDA Approval for ZIRCON Renal Cancer Imaging
Melbourne (Australia) – 23 January 2020. Telix Pharmaceuticals Limited is pleased to announce that the FDA has approved the ZIRCON...
News
NDA Clinical Briefing Package Submitted to the US FDA
Melbourne (Australia) – 27 Dec 2019. Telix Pharmaceuticals Limited is pleased to announce that it has submitted a complete clinical...
News
TLX101 for Brain Cancer IPAX-1 Study Update
Melbourne (Australia) – 23 December 2019. Telix Pharmaceuticals has released an update on the progress of its TLX101 product being...
News
ZIRCON Phase 3 IND Submitted to the US FDA
Melbourne (Australia) – 24 December 2019. Telix Pharmaceuticals Limited is pleased to announce that it has submitted a Phase 3...
News
University of Melbourne collaboration with Telix receives Cancer Australia research grant
Melbourne (Australia) – 19th December 2019. Telix Pharmaceuticals Limited (ASX: TLX) is pleased to announce that Telix collaborator Professor Frédéric...
News
Telix Pharmaceuticals and ATONCO Partner for Bladder Cancer
Melbourne (Australia) and Nantes (France) – 16, Dec 2019. Telix Pharmaceuticals Limited and French company ATONCO S.A.S today announce that...
News
Webcast of CEO’s presentation to Jefferies 2019 London Healthcare Conference
Melbourne (Australia) – 25th November 2019. Telix Pharmaceuticals Limited has today announced that Group CEO, Dr Christian Behrenbruch, presented at...